ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Sexual Health Day 1 Session 2
Indigenous Australians have a disproportionally higher levels of Chlamydia and Gonorrhoea compared to non indigenous Australians.
Point of care testing for Chlamydia and Gonorrhoea in Remote North Australia has proven to be highly effective in ensuring rapid diagnosis and treatment of those infected.
POC testing has reduced time to treat from average of 19 days down to 72% less than 3 days and the majority treated in under 7 days.
Real time testing of Ciprofloxacin resistance in Gonorrhoea is emerging with testing for genetic patterns associated with Ciprofloxacin sensitivity as well as resistance.
Pristinamycin is a novel new antibiotic with dual action that may prove to be helpful in treating macrolide resistant Mycoplasma Genitalium. In doses of 2- 4 g daily it has shown 75% cure rate in previously failed treatment of MG. Pristinamycin has shown an acceptable side effect profile and safety in pregnancy when given unknowingly.
New PCR test kits are emerging that allow the detection of MG resistance detecting 5 different genetic markers. This may aid better directly therapies for treatment of MG.
Changes in vaginal microbiota have been associated with increased risk of bacterial vaginosis.
Risk factors include, reduced levels of lactobacillus, increased exposure to different vaginal flora via new sexual partners, high levels of Gardinerella as well as changes in stability and increased diversity of the vaginal flora.
Female partners of men diagnosed with pathogen negative non-gonococcal urethritis should be notified, tested and ?treated with review of partners data showing increased rates of symptoms in female partners (60%) and a 12% association with PID.